Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -9115.35% is 12% below its 4-year average of -8105.42%, around the middle of its 4-year range (-15092.31%–-1779.21%).
15.71% above its 12-month average of -10814.81%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -10774.51%.
EBITDA MARGIN
-9115.35%
EBITDA MARGIN AVG TTM
-10814.81%
EBITDA MARGIN AVG 3Y
-9085.47%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+15.71%
CURRENT VS 3Y AVG
-0.33%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Envoy Medical, Inc.
Market Cap
$50.25M
EBITDA Margin
-9115.35%
TTM Avg
-10814.81%
3Y Avg
-9085.47%
5Y Avg
N/A
Market Cap
$50.51M
EBITDA Margin
-108.45%
TTM Avg
-10676.44%
3Y Avg
-10454.97%
5Y Avg
-429870.64%
Market Cap
$49.96M
EBITDA Margin
-10794.00%
TTM Avg
-9994.66%
3Y Avg
-8986.60%
5Y Avg
-8678.68%
Market Cap
$49.50M
EBITDA Margin
-203.44%
TTM Avg
-129.78%
3Y Avg
-288.25%
5Y Avg
-438.27%
Market Cap
$51.58M
EBITDA Margin
-61570.00%
TTM Avg
-181077.86%
3Y Avg
-90538.93%
5Y Avg
-60359.29%
Market Cap
$52.95M
EBITDA Margin
-36.23%
TTM Avg
-36.23%
3Y Avg
-36.23%
5Y Avg
-36.23%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Envoy Medical, Inc. (COCH) | $50.25M | -9115.35% | -10814.81% | -9085.47% | N/A |
| Apollomics, Inc. (APLM)vs › | $50.51M | -108.45% | -10676.44% | -10454.97% | -429870.64% |
| Clene Inc. (CLNN)vs › | $49.96M | -10794.00% | -9994.66% | -8986.60% | -8678.68% |
| Celularity Inc. (CELU)vs › | $49.50M | -203.44% | -129.78% | -288.25% | -438.27% |
| biote Corp. (BTMD)vs › | $49.40M | 20.40% | 19.12% | 4.66% | 12.12% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.58M | -61570.00% | -181077.86% | -90538.93% | -60359.29% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.95M | -36.23% | -36.23% | -36.23% | -36.23% |
| ImageneBio Inc (IMA)vs › | $53.01M | -5927.25% | -3470.39% | -2050.54% | -1465.25% |
Gross Margin
-262.7%
EBITDA Margin
-9115.4%
Operating Margin
-9240.7%
Net Margin
-11304.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -10774.51% |
| 2026-03-31 | -15092.31% |
| 2025-12-31 | -8406.67% |
| 2025-09-30 | -13409.52% |
| 2025-06-30 | -6391.03% |
| 2025-03-31 | -10969.57% |
| 2024-12-31 | -10657.14% |
| 2024-09-30 | -8794.64% |
| 2024-06-30 | -7085.29% |
| 2024-03-31 | -8244.07% |
| 2023-12-31 | -7026.32% |
| 2023-09-30 | -4195.00% |
| 2023-06-30 | -7065.08% |
| 2023-03-31 | -4800.00% |
| 2022-12-31 | -14400.00% |
| 2022-09-30 | -3112.28% |
| 2022-06-30 | -3694.92% |
| 2022-03-31 | -1779.21% |
